Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore is a numbers guy. You can tell by the thoughtful, considered way he reflects on his experience that.
Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara s human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.Read Full Article▸
On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.Read Full Article▸
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).Read Full Article▸
Anatara Lifesciences Limited (ASX:ANR) Chair Transition
Chair TransitionMelbourne, July 26, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, is pleased to announce the transition of Dr David Brookes from Non-Executive Director to Chairman. Sue MacLeman will continue on the Board, transitioning from Chair to Non-Executive Director.
The Board determined that, having successfully steered the Company following its decision to focus on the development of products and technologies in the human health sector with a focus on gut health, the time was now right for Dr Brookes to transition to the role of Chair as the Company progresses towards clinical trials.